SCHIZOPHRENIA 1 (Disorder)Cognitive functionMental healthDrugPhase 2
What this study is
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
What's being tested
- DSP-2342
Intervention · DRUG
a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.
Study details
- Sponsor
- Johns Hopkins University
- Conditions
- SCHIZOPHRENIA 1 (Disorder)
- Enrolling
- 20 people
- Starts
- 2027-01-01
- Est. completion
- 2028-06-30
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 50 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Right-handed, participants with schizophrenia between the ages of 18-50 years.
You can't join if
- Current substance misuse
- Pregnancy or breast feeding
- Subjects with electrocardiographic abnormalities (particularly QTc prolongation)
- Subjects with renal impairment
- Subjects with hepatic impairment
- Past or current neurological disorder (including stroke, brain tumor, epilepsy, Alzheimer's, Parkinson's or Huntington's disease)
- Non-schizophrenia cause of cognitive impairment
- Uncontrolled medical disorder that may interfere with cognition or compromise safety
- Head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
- Having a contraindication to MRI, including a pacemaker, defibrillator or other medical implant, other metal objects, or claustrophobia, or for having braces or other metal in the head region (likely to create an artifact on the MRI scans).
- Significant suicidal ideation
- Recent history of electroconvulsive therapy
- Medication changes in the past six weeks
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openjohns Hopkins University
Baltimore, Maryland, United States
- akira sawa, professor,, MD · Contact443-846-1409asawa1@jhmi.edu
Study team
Sponsor
Johns Hopkins University
Study ID IRB00515260
Principal investigator
Akira Sawa, MD
Johns Hopkins University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.